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Abstract 
The fluoropyrimidine drugs 5-fluorouracil and its oral prodrug capecitabine remain first line 
therapy for solid tumours of the neck, breast and colon. However, significant and 
unpredictable toxicity affects about 10-25% of patients depending upon the mode of 5-
fluorouracil delivery. The pharmacokinetics of thymine (5-methyluracil) may provide an 
approach for screening for 5-fluorouracil toxicity, based on the rationale that thymine is a 
close structural analogue of 5-fluorouracil and is catabolized by the same enzymatic pathway. 
Oral thymine loading tests were performed on 12 healthy volunteers. Each subject was given 
a single oral dose of 250 mg thymine in capsule form. Blood, urine and saliva samples were 
collected pre-dose and up to 5 h post-dose. Concentrations of thymine, and its catabolites 
dihydrothymine and ß-ureidoisobutyrate were analysed by HPLC-tandem mass spectrometry 
in plasma, urine and saliva. The pharmacokinetic data of healthy volunteers were analysed 
assuming a non-compartmental model. Thymine peaked quickly (30-45 min) in plasma to a 
maximum concentration of 170+185 µg/L (mean+SD). Clearance was high (mean 57.9 
L/h/kg) exceeding normal human liver blood flow, suggesting low systemic bioavailability; 
urinary recovery of the thymine dose was low (<1%). Apparent formation rate-limited 
kinetics were observed for dihydrothymine, and the plasma concentration of dihydrothymine 
was consistently 10-fold higher than that of thymine.  Plasma ß-ureidoisobutyrate 
concentrations, on the other hand, were similar to that of thymine. Genotyping confirmed that 
pathological mutations of the DPYD gene were absent. The urinary excretion ratio of 
thymine/dihydrothymine was informative of the maximum concentration. Saliva thymine was 
highly variable. These data are potentially useful as a basis for developing of a screening 
procedure to prospectively identify patients who are at risk of toxicity from fluoropyrimidine 
drugs. 
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1. Introduction 
The fluoropyrimidine drugs remain an important class of anticancer drugs and are an 
essential component of chemotherapy for solid tumours. 5-fluorouracil (5FU) is used as first 
line therapy for tumours of the head and neck,  colon and rectum (Longley et al., 2003) and 
for adjuvant treatment in breast cancer (i.e. FAC, FEC). Capecitabine, an oral prodrug of 
5FU, is utilised as single-agent therapy for breast and bowel cancer (Walko & Lindley., 
2005). Within the normal population there is variation in the response to 5FU and 
capecitabine, with most patients experiencing some diarrhoea, mild stomatitis and nausea. 
More recent constant infusion modalities have lowered the rate of severe toxicity, but 
injurious or life-threatening mucositis or bone marrow suppression still occurs with standard 
doses of 5FU in approximately 11% of patients on infusion therapy and 25% with bolus 
therapy (Andre et al., 2003; Twelves et al., 2005).  
Part of the variability of treatment response to fluoropyrimidines, in particular toxicity, can 
be attributed to pharmacogenetic factors. However, despite several decades of effort, a 
routine method for predicting which individuals will be susceptible to significant grade 3 and 
4 toxicity from 5FU or capecitabine is not established. The basic pharmacological assumption 
for 5FU toxicity here is that it arises from increased systemic exposure to 5FU as a result of 
reduced clearance of 5FU and/or low catabolism via the endogenous pyrimidine pathway. 
Fig. 1 illustrates how pyrimidine – and 5FU –  catabolism involves a multi-step pathway. 
Efforts to redress the issue of 5FU toxicity have focussed on a genetic deficiency of the first 
catabolic step dihydropyrimidine dehydrogenase (DPD), which in humans is encoded by the 
DPYD gene. However, partial deficiency of DPD activity explained retrospectively only 
about one-third to one-half of recorded cases of severe 5FU toxicity, limiting the sensitivity 
and utility of any prospective DPD screening test (van Staveren et al., 2013). Therapeutic 
drug monitoring (TDM) of 5FU is inconsistently utilised because administration of a test 
dose of 5FU is almost universally avoided due to the perceived risk of inducing tumour 
tolerance, while administration of a full dose for TDM does not avoid the usual clinical risk 
of toxicity, which can be life-threatening. 
Sumi and coworkers (1998) demonstrated the possibility of detecting carriers of DPD and 
dihydropyrimidinase deficiencies by measuring basal urinary excretion of thymine and 
dihydrothymine, having found that neither urinary uracil nor dihydrouracil concentration 
readily detects carriers. Accordingly, we proposed that thymine might provide a better 
approach for screening for deficiency of DPD and the second catabolic step, 
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dihydropyrimidinase, based on the following rationale: (i) Thymine (5-methyluracil) is a 
close structural analogue of 5FU and is catabolized by the same enzymatic pathway (Fig. 1); 
(ii) Compared to uracil, endogenous thymine concentrations in human urine and plasma are 
much lower and less variable (Simmonds et al., 1990; Ni et al., 2013), which would result in 
a lower level of endogenous metabolic ‘noise’, thereby potentially providing increased 
sensitivity; (iii) Purified thymine is inexpensive, readily available, and is stable at room 
temperature over long periods; (iv) Sparse blood level data published more than 50 years ago 
(Spray, 1958) indicated that thymine appears to be rapidly absorbed and eliminated after oral 
dosing, and has a short elimination half-life which would potentially make a PK-based 
screening test convenient for cancer patients; (v) thymine is a naturally occurring compound 
in humans which appears safe in oral doses up to at least 2 g (Spray, 1958); (vi) There is no 
salvage of thymine into nucleic acids or other synthetic pathways which would otherwise 
confound any PK data. 
Therefore, with the aim of developing a new PK-based screening test for fluoropyrimidine 
toxicity, we collected preliminary data on the human PK disposition of thymine and its 
sequential metabolites dihydrothymine and ß-ureidoisobutyrate, following administration of 
an oral dose of thymine to twelve healthy volunteers.  
 
2. Participants and methods 
2.1 Participants 
Prior ethics approvals were obtained from the Human Research Ethics Committees of Mater 
Health Services, and The University of Queensland. All subjects had provided signed 
informed consent. Twelve male Caucasian volunteers, aged 37-58 years (mean + SD = 49 + 
8.4), were recruited. All volunteers were non-smokers, moderate or non-drinkers, and were 
healthy based on physical/medical assessments: mean height 1.8 + 0.036 m, weight 82 + 5.8 
kg and BMI 25.5 + 1.34 kg/m
2
. ECG, serum biochemistry and haematology testing, as well 
as a physical examination by a physician, were conducted within two days of the study date. 
None of the subjects had a history of drug hypersensitivity or a clinically significant illness 
up to at least four weeks before the study nor had any subject been hospitalized during the 
previous three months.  
2.2. Materials 
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Commercially available powdered thymine (>99% purity, Sigma-Aldrich Ltd, Sydney, NSW, 
Australia) was verified for its suitability for human oral consumption according to 
specifications of the British Pharmacopeia 2004. Physical, microbiological and chemical 
analyses, including by HPLC-linked triple quadrupole mass spectrometry (LC-MS/MS), were 
undertaken and met the specifications of the Australian Therapeutic Goods Administration 
such that thymine was acceptable for clinical trial registration. Powdered dihydrothymine 
material was purchased from Sigma-Aldrich Chemical Co (St Louis, MO, USA). ß-
ureidoisobutyrate is not commercially available, therefore it was synthesised by the chemical 
reduction of dihydrothymine using the method of Fink and coworkers (1956), and tested for 
purity by melting point analysis and LC-MS/MS. All other reagents and standards used for 
HPLC were of analytical reagent quality. 
2.3. Dosing and sampling 
On the study day, the subjects had a meat-free, light breakfast approximately 2 h before 
thymine administration, and were closely observed by medical staff during, and 1 h after, the 
blood sampling period. Powdered thymine (250 mg) was encapsulated using a capsule-filling 
machine by hospital pharmacy staff, and involved no excipients. The thymine was 
administered in a single hard gelatin capsule to avoid oral contamination of saliva. Each 
subject swallowed the capsule with 100 mL of tap water at approximately 09:00. Blood was 
drawn via an indwelling venous catheter at 0 h (pre-dose), then nominally at 0.25, 0.5, 0.75, 
1, 1.5, 2, 3, 4 and 5 h, post-dose. Mixed unstimulated saliva samples were obtained via 
passive drool into a plastic vial when blood samples were collected. Urine was collected 
nominally at 0, 1, 2, 3 and 5 h, post-dose.  Water was allowed ad libitum during the sampling 
period and a light lunch was provided 3 h post-dose.  
2.4. Analyses of thymine, dihydrothymine and ß-ureidoisobutyrate 
Plasma and urine concentrations of thymine, dihydrothymine and ß-ureidoisobutyrate were 
measured using a validated rapid method based on LC-MS/MS, using an atmospheric 
pressure chemical ionisation (APCI) interface, as described previously by some of us (Ni et 
al., 2013). This method also was applied with minor modifications to analyse thymine and 
dihydrothymine in saliva samples. Briefly, saliva was ultrafiltered to remove particulate 
matter and mucin by centrifuging in 0.5 mL, 50 kDa cutoff Amicon ultrafilters (Merck Pty. 
Ltd., Australia) at 9500 g for 10 min at room temperature. The ultrafiltrate was treated 
similarly to plasma and urine, by mixing 200 µL of sample with 1 mL of an internal standard 
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(d4-thymine in acetonitrile), followed by vortex-mixing and centrifuging to remove any 
precipitate. The supernatant was evaporated to dryness under nitrogen gas, then redissolved 
in 150 µL of 0.1% formic acid in deionised water. Salivary ß-ureidoisobutyrate was not 
analysed, as its measurement had unacceptably high variability by this LC-MS/MS method 
(Ni et al 2013).  
2.5. Pharmacokinetics 
The pre-dose (natural baseline) plasma concentration (C0), maximum plasma concentration 
(Cmax), and time to reach the maximum plasma concentration (Tmax) were recorded directly 
from the observed data. The area under the curve (AUC) was calculated by trapezoidal 
integration with linear interpolation between concentration-time data points; apparent 
systemic clearance (CL/F) and apparent volume of distribution (V/F) were calculated by non-
compartmental analysis; the first-order elimination rate constant (λ) was estimated as the 
slope of the line of best fit of the terminal phase using linear regression of logarithm of 
concentration on time (T); terminal half-life (T0.5) was calculated by the expression, T0.5 = 
0.693/λ. The amount of thymine excreted in urine (X0-T) was estimated by the product of the 
concentration multiplied by urine volume obtained in a given collection period summed over 
all collection periods to provide the cumulative amount excreted from the dosing time up to 
sampling time, T.  
2.6. Genotyping of DPYD 
DPYD exons and approximately 10 bases of each flanking intronic sequence were amplified 
by PCR. Subsequently, purified amplicons were sequenced and analysed for mutations 
essentially as described previously (van Kuilenburg et al., 2000). This covered the presence 
of known functional mutations; the deep intronic mutant c.1129-5923C>G/hapB3 (Amstutz 
et al., 2009) was not sequenced. 
 
3. Results 
There was marked inter-subject variability in the individual concentration-time profiles. The 
number of observed log-linear ‘compartments’ varied from one to three, which together with 
the limited number of data points precluded the use of non-linear regression. However, using  
non-compartment analysis the CL/F of thymine could be readily calculated from the AUC0→T 
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data, corrected for the pre-dose plasma concentrations, since the respective values of the pre-
dose and the post-dose concentrations at the final sampling time differed insignificantly 
(P>0.05).  
Fig. 2 (panel A) shows mean (± SD) plasma concentration data for thymine, dihydrothymine 
and ß-ureidoisobutyrate at baseline (pre-dose) and after thymine administration. The short 
delay lag of approximately 15-30 min in the appearance of thymine in plasma and the absence 
of multiple peaks in most profiles suggested that there were few, if any, 
disintegration/dissolution limitations for encapsulated thymine, or ‘dose-dumping” from the 
stomach into the intestinal tract. 
Orally-administered thymine was well tolerated with no apparent adverse effects reported by 
the subjects or observed by the investigators.  All subjects were genotyped for DPYD and no 
pharmacogenetic mutations (excluding the B3 haplotype) were found. Thymine was rapidly 
absorbed and attained a mean ± SD peak concentration (Cmax) of 170 ± 185 µg/L at 1.06 ± 
0.415 h. The disappearance of thymine, dihydrothymine and ß-ureidoisobutyrate from plasma 
was rapid; the terminal elimination phases of thymine and dihydrothymine were 
approximately parallel, with similar T0.5 values (0.972 ± 0.470 h and 0.922 ± 0.373 h, 
respectively) indicating likely formation rate-limited kinetics for dihydrothymine from 
thymine. 
The collective amount of thymine, dihydrothymine and ß-ureidoisobutyrate in urine 
measured over the sampling period amounted to less than 0.5% of the dose. The PK 
parameters for thymine, dihydrothymine and ß-ureidoisobutyrate in plasma and urine are 
summarised in Table 1 (Subjects 1 and 2 provided plasma and urine samples only to 3 h). The 
CL/F for thymine was 57.9 ± 49.4 L/h/kg, and V/F was 66.6 ± 59.4 L/kg.  
Salivary concentration-time data, as shown in Fig. 2 panel B, were available only for thymine 
and dihydrothymine because of assay limitations for ß-ureidoisobutyrate. Although the mean 
salivary profiles tended to track the corresponding plasma concentration-time profiles, there 
was very high inter-subject variability, including in the pre-dose concentrations. The salivary 
Tmax values for thymine and dihydrothymine (1.0 ± 0.32 h and 1.2 ± 0.36 h respectively) were 
comparable to the corresponding plasma values (Table 1), while the mean salivary Cmax 
values for thymine (760 ± 994 µg/L) and dihydrothymine (1056 ± 661 µg/L) were markedly 
higher than the respective plasma concentrations (Table 1). Fig. 3 shows a linear relationship 
between the ratio of total urinary thymine/dihydrothymine excretion over 3-5 h versus the 
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logarithm of thymine Cmax (line-of-best-fit, r = 0.87); the relationship between urinary 
thymine versus log thymine Cmax was also linear, demonstrating the effect of plasma thymine 
concentration on its excretion in urine but the linear correlation coefficient of the line-of-best-
fit (r = 0.81) was slightly weaker.   
Basal plasma dihydrothymine concentrations ranged from 2-fold to 9-fold higher than thymine 
suggesting that, since the half-lives of thymine and dihydrothymine were similar, dihydrothymine 
may have a smaller V/F than thymine. To test whether there were any differences in the distribution 
of thymine caused by exclusion of dihydrothymine from erythrocytes, the concentrations of thymine 
and dihydrothymine in both plasma and whole blood were measured in a sample from a subject 
taken at 0.75 h post-dose. Thymine concentrations were 230 µg/L in plasma and 470 µg/L in whole 
blood, while the dihydrothymine concentrations were 490 µg/L and 1070 µg/L, respectively; 
therefore, the dihydrothymine/thymine ratios were similar in plasma (2.1) and in blood (2.3). 
 
4. Discussion   
Predicting 5FU toxicity has eluded researchers for decades, despite a strong clinical need for 
a simple test. Studies have focused on polymorphism of the DPD gene, but screening of 
DYPD has been complicated by the large size of the gene (23 exons) and that mutant alleles 
are diverse. The most commonly described loss-of-function polymorphism (DYPD*2A: 
c.1905+1G>A) accounts for ~40% of cases of low DYPD activity and about a quarter (24-
28%) of all cases of 5FU toxicity among most European Caucasians (van Kuilenburg et al., 
2002; Yen and McLeod, 2007). A large number of other mutations have a much lower 
incidence (Offer et al., 2014). The DPYD c.1129-5923C>G/hapB3 deep intronic mutation has 
been associated with half of severe toxicity and a relatively high carrier rate of 4.6% in a 
Swiss population (Froehlich et al., 2015) but its applicability to other, non-Swiss populations 
requires confirmation. The low sensitivity of DPYD genotyping presently makes prospective 
genetic testing of patients unattractive, with genotyping not generally adopted for prospective 
testing (van Staveren et al 2013). 
The need to seek alternative screening approaches to predict fluoropyrimidine toxicity has 
spawned various pharmacokinetic (PK) methods that have centred largely upon uracil as an 
endogenous marker, typically determining the plasma concentration ratio of uracil to its 
catabolite dihydrouracil (or vice versa) as a surrogate for DPD activity (Garg et al., 2002; 
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Jiang et al., 2004; Remaud et al., 2005; Ciccolini et al., 2006; Sistonen et al., 2014). More 
recently, a retrospective study administering oral uracil dose-loading to known carriers of 
DPD deficiency has provided encouraging results, identifying DPD-deficient patients from 
plasma uracil concentrations 60 min post-loading (van Staveren et al., 2011). 
Our study reports the first human pharmacokinetic data of thymine together with its 
catabolites dihydrothymine and ß-ureidoisobutyrate in healthy adult subjects. We found the 
basal concentration of thymine in plasma to be low, with a relatively small amount of 
variability (11 + 3 µg/L), thus providing good sensitivity for the loading assay at low doses. 
This was in contrast to the wide discrepancies reported for basal plasma uracil concentrations, 
from 10 ug/L (Remaud et al., 2005) to 5 mg/L (Jiang et al., 2002). 
Thymine was rapidly absorbed following an oral 250 mg dose and reached peak plasma 
concentrations which averaged 16-fold higher than the baseline (pre-dose) concentration. 
Plasma concentrations then declined to baseline levels within 3-5 h, in a log-linear profile 
comprising up to three identifiable compartments. The actual CL and V could not be 
estimated since intravenous dosing of thymine was not possible, thus, the  values of these 
parameters are predicated on the  fraction (F) of the oral dose which is absorbed systemically 
from the gut. Likewise, the actual values CL and V of the sequential catabolites 
dihydrothymine and ß-ureidoisobutyrate also depend on F, and also on the  fraction of 
substrate enzymatically converted, respectively, from thymine to dihydrothymine, and from 
dihydrothymine to ß-ureidoisobutyrate. The high estimated CL/F of 57.9 L/h/kg for thymine 
far exceeded normal human liver blood flow, suggesting low systemic bioavailability perhaps 
arising from either high first-pass clearance (Gu et al., 1998) and/or capacity-limited 
pyrimidine transport (active or facilitated) from the gut (Bronk and Hastewell, 1987; 
Wohlhueter et al., 1980; Li et al., 2002). 
Interestingly, the mean CL/F of uracil following oral administration of a 500 mg/m
2
 
suspension to 11 healthy volunteers was 1.05 L/h/kg (van Staveren et al., 2011), which is 50-
fold lower than we report here for thymine, despite elimination half-lives of uracil and 
thymine being comparable.  
Human data for intravenous thymine has not been reported, however the average CL of 
thymine reported in healthy dogs following an intravenous bolus was 2.6 L/h/kg (Covey and 
Straw, 1983). It is reasonable to assume that since that CL per kg of 5FU in dogs and humans 
is comparable (Maring et al., 2002; Covey and Straw, 1983), then this comparison should 
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also hold for thymine, which is a close structural analogue of 5FU. If so, the systemic 
bioavailability of thymine in our subjects is estimated to be less than 5%.  
DPD is widely distributed in the human body although the relative contributions of these 
tissues to metabolism is unknown, so thymine catabolism to dihydrothymine may also occur 
in tissues other than the liver (Naguib et al., 1985; Gonzalez et al., 1995; van Kuilenburg et 
al., 2006). We found that the baseline plasma concentrations of dihydrothymine were 
markedly higher than those for thymine (with a mean plasma dihydrothymine/thymine ratio 
of 8.1). Plasma dihydrothymine remained higher than thymine after dosing, which suggested 
rapid conversion of thymine to dihydrothymine, then dihydrothymine to ß-ureidoisobutyrate, 
soon after thymine reaches the systemic circulation. Moreover, the parallel terminal 
elimination phases, ranging from 3-5 h in most subjects for thymine and dihydrothymine, 
suggested formation rate-limited kinetics for the conversion of thymine to dihydrothymine, 
and to a lesser extent for dihydrothymine to ß-ureidoisobutyrate. In contrast, the ratio of basal 
plasma dihydrouracil/uracil in healthy adults varies greatly in other reports, from a mean of 
0.67 (Ciccolini et al., 2004) to 9.05 (Remaud et al., 2005). An explanation of the wide 
discrepancies in these ratios may be methodological, as HPLC with UV detection below 210 
nm is poorly selective in the assay of biological matrices (Ciccolini et al., 2004). Following 
uracil oral loading of normal volunteers, plasma dihydrouracil does not track uracil, and was 
far lower than uracil for up to 120 min (van Staveren et al., 2011), which contrasts with our 
thymine data. 
Assuming that all dihydrothymine in plasma was formed only from thymine metabolism, one 
explanation for our observation is that the volume of distribution of dihydrothymine is much 
less than for thymine, as has been rationalised for some other drugs exhibiting similar 
profiles, e.g. propranolol (Walle et al., 1979).  By contrast, the plasma concentrations of ß-
ureidoisobutyrate were only slightly less than the corresponding orally-administered thymine 
concentrations. Since plasma and not whole blood was used as the analytical matrix, there 
was a possibility that these observations were caused by a differential distribution between 
formed elements (e.g. erythrocytes) and plasma, since purine nucleobases (e.g. adenine, 
guanine) may be actively transported into erythrocytes via high-affinity facilitated diffusion 
(Domin et al., 1988). However, data from one of our subjects showed that the concentrations 
of both thymine and dihydrothymine following dosing were approximately 2-fold higher in 
whole blood than plasma, demonstrating that there did not appear to be a selective exclusion 
of dihydrothymine from erythrocytes. In support, uracil, which has a similar molecular 
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structure to thymine, has been shown by others to have a low affinity (Km ~5,800 μM) for 
erythrocyte permeation (Domin et al., 1993).   
Alternately, the high plasma dihydrothymine/thymine ratio may be based on differences in 
the affinities of the enzymes that break down thymine and dihydrothymine, i.e. DPD and 
dihydropyrimidinase, respectively. Lu and coworkers (1992) reported Vmax/Km values (i.e. 
as a measure of enzyme efficiency) of purified human liver DPD for thymine and uracil of 
122 and 146 L/min/mg, respectively, which are comparable with the values reported by them 
for purified DPD from rat liver (333 and 240 L/min/mg), and bovine liver (179 and 130 
L/min/mg). Although human liver dihydropyrimidinase has not been purified, much lower 
Vmax/Km values  for dihydrouracil and dihydrothymine were reported by Kikugawa and 
coworkers (1994) for purified rat liver, and by Brooks and coworkers (1983) for bovine liver 
dihydropyrimidinase  (65 and 36 L/min/mg, respectively). Given the constant bodily flux of 
these pyrimidines through the catabolic pathway, it can be predicted that the 
dihydropyrimidine form will be constantly elevated because dihydropyrimidinase, rather than 
DPD, acts as the rate-limiting enzyme due to its lower substrate affinity and efficiency; this 
conclusion has been supported by others (Traut and Loechel, 1984; Naguib et al., 1985). 
Less than 1% of the administered thymine dose was excreted unchanged in urine. In contrast, 
Spray (1956) administered a dose which was 8-fold higher than used here, and reported that 
approximately 9% of the dose was excreted over 3 h, although those data were obtained using 
a microbiological assay that had disadvantages, particularly lower sensitivity, compared to 
state-of-the-art chromatography. Nonetheless, this raised the possibility of dose-dependent 
saturation of the catabolism of thymine (and hence 5FU) at higher doses, as reported in dogs 
(Covey and Straw, 1983). A dose-ranging PK study to test this hypothesis in humans was not 
possible during our investigations. However, van Staveren and coworkers (2011) reported 
two doses for a uracil loading test: 500 mg/m
2
 (i.e. approximately 900-1000 mg, or 4-fold 
higher than our dose) and 1000 mg/m
2
 (approximately 8-fold higher than used here) and 
found linear PK, thereby providing evidence that there was no saturation of the catabolic path 
by uracil at these higher doses.  
Urinary excretion of thymine factored by dihydrothymine excretion (i.e. urine 
thymine/dihydrothymine) was predictive of the Cmax for thymine. It would be expected that 
urinary clearance of thymine would be a predictor of its Cmax, because renal clearance is 
partially a function of plasma concentration, but the correlation of Cmax was lower with 
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urinary thymine alone. Further study of the urinary thymine/dihydrothymine ratio is 
warranted, as this may provide a simpler method of predicting fluoropyrimidine toxicity, in 
combination with a thymine load, compared to blood sampling. In one study, the mean basal 
urinary ratio of uracil/dihydrouracil in 167 healthy subjects was 63.3/23.8, i.e. 2.66 (Hayashi 
et al., 1996): this value is within our reported range of 0.46-2.79 for the basal urinary ratio of 
thymine/dihydrothymine (Fig. 3).  
Saliva collection was included in the present study protocol because it provides a potentially 
more convenient and safer alternative to venepuncture, especially in any prospective test for 
pyrimidine toxicity. Although there was a general trend for the mean salivary concentration-
time data of thymine and dihydrothymine to track the mean plasma profiles, there was high 
inter-subject variability in the saliva concentrations. In particular, salivary thymine 
concentrations were mostly higher than dihydrothymine, which contrasted with our plasma 
data where basal dihydrothymine levels were consistently much higher than thymine, 
demonstrating that saliva is not simply a filtrate of plasma with respect to pyrimidine bases. 
Therefore, further investigations using saliva as the biological sample matrix were 
discontinued.   
 
5. Conclusion  
The PK for thymine and its catabolites dihydrothymine and ß-ureidoisobutyrate were studied 
following administration of a 250 mg oral dose of thymine to healthy adult volunteers, and 
provisional ranges for PK parameters were established. Baseline plasma dihydrothymine was 
approximately an order of magnitude higher than thymine, an interesting phenomenon that 
may arise from enzymatic flux through the catabolic pathway rather than volume of 
distribution influence. Urine recovery was low but the ratio of urinary 
thymine/dihydrothymine was informative. Importantly, these preliminary data will inform the 
development of a PK-based screen for fluoropyrimidine toxicity, which we are presently 
studying in cancer patients.  
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LEGENDS FOR FIGURES 
 
Fig. 1. Catabolic pathway for 5-Fluorouracil (5FU) and Thymine (THY). 
 
Fig. 2(A). Plasma concentration versus time. Plots show thymine (THY), dihydrothymine 
(DHT) and ß-ureidoisobutyrate (UIB) after oral administration of 250 mg thymine to 12 
healthy adult volunteers. Note the logarithmic scale of the concentration axis (data points are 
shown as the mean ± SD).  
 
Fig. 2(B). Salivary concentration versus time. Plots show thymine (THY) and 
dihydrothymine (DHT) after oral administration of 250 mg thymine to 12 healthy adult 
volunteers (data points are shown as the mean ± SD).  
 
Fig. 3. Cmax values for plasma thymine (THY) against the ratio of urinary 
thymine/dihydrothymine (THY/DHT). The line of best fit is described by: y = 0.882 · Ln (X) 
- 2.76; Pearson correlation coefficient, r = 0.872. 
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Figure 3 
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Table 1.  
Plasma PK parameters of THY, DHT and UIB for 12 healthy male subjects 
 
Parameter                        THY                              DHT                                  UIB       
  DHT 
 
Mean (SD) Mean (SD) Mean (SD) 
C0 (µg/L) 10.6 (2.95) 85.5 (17.9) 8.91 (3.48) 
Cmax(µg/L) 170 (185) 550 (224) 27.5 (8.43) 
Tmax (h) 1.06 (0.415) 1.21 (0.334) 1.38 (0.42) 
AUC (µg.h/L) 107 (97.5) 586 (310) 34.5 (12.7) 
CL/F (L/h/kg) 57.9
a
 (49.3) 7.16
b
 (4.39) 107
c
 (58.4) 
V/F (L/kg) 66.6
a
 (59.4) 8.21
b
 (4.67) 422
c
 (429) 
T0.5 (h) 0.972 (0.470) 0.922 (0.373) 2.48 (1.04) 
X0-Tf (mg)  0.587 (0.561) 0.380 (0.177) 0.228 (0.107) 
λ (/h) 1.22 (1.68) 1.10 (1.25) 0.313 (0.0964) 
 
THY: thymine; DHT: dihydrothymine; UIB: ureidoisobutyrate; C0: Pre-dose (baseline) plasma 
concentration; Cmax: Maximum plasma concentration; Tmax: Time to reach Cmax; AUC: Area-under-
the-curve; CL/F: Clearance; V/F: Volume of distribution; T0.5: Terminal half-life; X0-T: Amount 
excreted in urine to final sample time T; λ: Elimination rate constant; F: Oral bioavailability of THY. 
a
Apparent CL and V predicated on F; 
b
Apparent CL and V predicated on F, and the fraction of 
thymine dose catabolized to DHT; 
c
Apparent CL and V predicated on F, the fraction of thymine dose 
catabolized to DHT, and the fraction of DHT catabolized to UIB. 
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